IRVINE, Calif.--(BUSINESS WIRE)--Endologix, Inc. (Nasdaq: ELGX), developer and manufacturer of the Powerlink® System endovascular stent graft for the minimally invasive treatment of abdominal aortic aneurysms (AAA), announces that it is raising 2009 revenue guidance to $47 million to $50 million, representing growth of 25% to 33% compared with 2008 revenue. Previously Endologix projected 2009 revenues of $44 million to $46 million.
